#3988 MARS – A NOVEL SCORE TO PREDICT THE RISK OF ACUTE KIDNEY INJURY AFTER LIVING DONOR LIVER TRANSPLANT

Abstract

Abstract Background and Aims Acute kidney injury is common in liver transplant recipients with adverse effect on graft and patient outcomes. There are many studies on incidence, risk factors and outcomes of AKI post-LT in deceased donors, there is paucity of data about AKI in living donor liver transplant recipients (LDLT). LDLT is a difficult and prolonged surgery with inherent risk to donors, so it practised in only few centres across the world however there is little data of AKI in living donor liver transplant recipients (LDLT). Method This prospective observational study was undertaken to assess incidence, risk factors, patient graft outcomes and to develop a novel prediction model to identify recipients at risk for post-transplant AKI at the earliest possible time point after living donor liver transplantation in a tertiary care large volume centre in northern India. Results Incidence of AKI in our study was 31.7% with 13.5% requiring renal replacement therapy. Male gender, history of hepatorenal syndrome, use of intraoperative inotropes (Indicating Post reperfusion injury), MELD score >14, preoperative proteinuria >0.5 gram/day & estimated GFR <90 ml/min/1.73 m2 were significant risk factors for AKI within 1 month post-LDLT in logistic regression model. We devised a risk prediction score (The MARS score) which had a sensitivity of 81.36%, specificity of 88.19%, positive predictive value of 76.9%, negative predictive value of 91.06% and overall accuracy of 86.02% to predict AKI. AKI was associated with longer hospital stay, higher mortality and led to higher occurrence of chronic kidney disease after a median follow up period of 724 (635 – 794) days. Conclusion Our risk model (MARS) with an AUC of 0.925 performed better than all previously reported scores in DDLT & LDLT .The variables in our AKI risk prediction are simple to extract and use making it favourable in resource limited settings where access to newer biomarkers of kidney injury is limited. There is a need to apply the score in other cohorts to validate its applicability.